Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EQ Equillium	$0.36 -1.6%	$0.42	$0.34 ▼ $1.50	$12.97M	1.94	313,978 shs	42,091 shs
RPTX Repare Therapeutics	$1.49 +2.8%	$1.24	$0.89 ▼ $4.29	$63.91M	0.85	254,664 shs	145,140 shs
VRCA Verrica Pharmaceuticals	$0.58 -1.9%	$0.51	$0.38 ▼ $9.36	$53.97M	1.73	584,066 shs	265,036 shs
VTVT vTv Therapeutics	$16.53 +3.3%	$19.16	$12.12 ▼ $26.99	$52.80M	0.77	23,274 shs	735 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EQ Equillium	+3.36%	-1.76%	-7.80%	-53.29%	-65.19%
RPTX Repare Therapeutics	0.00%	+4.69%	+3.57%	+21.85%	-58.92%
VRCA Verrica Pharmaceuticals	+12.01%	+10.21%	+33.48%	-3.83%	-92.84%
VTVT vTv Therapeutics	-1.84%	-4.19%	-27.09%	-3.76%	-24.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EQ Equillium	2.8109 of 5 stars	3.2	5.0	0.0	2.2	1.7	0.6
RPTX Repare Therapeutics	2.5479 of 5 stars	3.3	3.0	0.0	2.2	2.5	0.6
VRCA Verrica Pharmaceuticals	3.6244 of 5 stars	3.1	1.0	4.7	0.6	3.3	0.6
VTVT vTv Therapeutics	2.6348 of 5 stars	3.5	5.0	0.0	3.5	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EQ Equillium	2.33	Hold	$3.00	726.45% Upside
RPTX Repare Therapeutics	2.50	Moderate Buy	$4.50	202.01% Upside
VRCA Verrica Pharmaceuticals	2.20	Hold	$8.00	1,271.04% Upside
VTVT vTv Therapeutics	3.00	Buy	$35.50	114.83% Upside

Current Analyst Ratings Breakdown

Latest EQ, VTVT, RPTX, and VRCA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/9/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/9/2025	VTVT vTv Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$36.00
4/8/2025	VRCA Verrica Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/28/2025	EQ Equillium	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/28/2025	EQ Equillium	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$3.00 ➝ $1.00
3/12/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/7/2025	RPTX Repare Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $5.00

(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EQ Equillium	$30.41M	0.43	N/A	N/A	$0.64 per share	0.57
RPTX Repare Therapeutics	$1.07M	59.56	N/A	N/A	$5.03 per share	0.30
VRCA Verrica Pharmaceuticals	$7.18M	7.52	N/A	N/A	$0.47 per share	1.24
VTVT vTv Therapeutics	$17K	3,105.73	N/A	N/A	($9.27) per share	-1.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EQ Equillium	-$13.34M	-$0.39	N/A	N/A	N/A	-10.05%	-20.68%	-10.77%	8/6/2025 (Estimated)
RPTX Repare Therapeutics	-$93.80M	-$3.01	N/A	N/A	N/A	-99.76%	-40.87%	-35.07%	N/A
VRCA Verrica Pharmaceuticals	-$67M	-$1.20	N/A	N/A	N/A	-625.06%	-591.84%	-141.63%	8/13/2025 (Estimated)
VTVT vTv Therapeutics	-$20.25M	-$3.01	N/A	∞	N/A	N/A	-184.64%	-47.29%	8/14/2025 (Estimated)

Latest EQ, VTVT, RPTX, and VRCA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	VTVT vTv Therapeutics	-$0.73	-$0.77	-$0.04	-$0.77	N/A	N/A
5/13/2025	Q1 2025	VRCA Verrica Pharmaceuticals	-$0.14	-$0.10	+$0.04	-$0.10	$2.53 million	$3.44 million
3/27/2025	Q4 2024	EQ Equillium	-$0.22	-$0.16	+$0.06	-$0.16	N/A	$4.39 million
3/20/2025	Q4 2024	VTVT vTv Therapeutics	-$0.87	-$0.55	+$0.32	-$0.55	N/A	$0.02 million
3/11/2025	Q4 2024	VRCA Verrica Pharmaceuticals	-$0.25	-$0.24	+$0.01	-$0.24	$1.30 million	$0.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EQ Equillium	N/A	N/A	N/A	N/A	N/A
RPTX Repare Therapeutics	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EQ Equillium	N/A	3.04	3.04
RPTX Repare Therapeutics	N/A	6.45	6.45
VRCA Verrica Pharmaceuticals	N/A	1.34	1.22
VTVT vTv Therapeutics	N/A	6.69	6.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EQ Equillium	27.05%
RPTX Repare Therapeutics	85.09%
VRCA Verrica Pharmaceuticals	42.45%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
EQ Equillium	31.60%
RPTX Repare Therapeutics	11.50%
VRCA Verrica Pharmaceuticals	42.60%
VTVT vTv Therapeutics	4.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EQ Equillium	40	35.72 million	24.70 million	Not Optionable
RPTX Repare Therapeutics	180	42.89 million	33.33 million	Optionable
VRCA Verrica Pharmaceuticals	40	92.49 million	26.18 million	Optionable
VTVT vTv Therapeutics	9	3.20 million	3.15 million	Not Optionable

EQ, VTVT, RPTX, and VRCA Headlines

Recent News About These Companies

Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Decreases By 24.1%

June 4 at 4:17 AM | americanbankingnews.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Down 24.1% in May

June 2 at 5:52 AM | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above Fifty Day Moving Average - Here's Why

May 26, 2025 | marketbeat.com

vTv resumes Phase III oral T1D drug study

May 21, 2025 | thepharmaletter.com

vTv Therapeutics Appoints Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer

May 19, 2025 | quiverquant.com

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 19, 2025 | globenewswire.com

vTv Therapeutics (NASDAQ:VTVT) Stock Passes Above 50-Day Moving Average - Here's Why

May 18, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Precision BioSciences (DTIL)

May 17, 2025 | theglobeandmail.com

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025 | globenewswire.com

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

May 15, 2025 | globenewswire.com

vTv Therapeutics Appoints Barry Brown as Interim CFO

April 11, 2025 | tipranks.com

vTv Therapeutics initiated with a Buy at H.C. Wainwright

April 9, 2025 | markets.businessinsider.com

HC Wainwright & Co. Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation

April 9, 2025 | msn.com

vTv Therapeutics cleared to resume clinical trial of diabetes therapy

March 26, 2025 | ncbiotech.org

vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year

March 21, 2025 | markets.businessinsider.com

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

March 20, 2025 | globenewswire.com

vTv Therapeutics Inc.: vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

March 18, 2025 | finanznachrichten.de

Alliance Global says clinical hold lift ‘de-risking’ event for vTv Therapeutics

March 18, 2025 | markets.businessinsider.com

vTv Therapeutics says FDA has lifted clinical hold on cadisegliatin program

March 17, 2025 | markets.businessinsider.com

vTv Therapeutics stock surges on FDA update

March 17, 2025 | au.investing.com

Vtv Therapeutics Shares Halted as FDA Clinical Hold on Diabetes Treatment Lifted

March 17, 2025 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?
By Gabriel Osorio-Mazilli | May 22, 2025
View Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?
Top 4 ETFs for China Exposure After Tariff Relief
By Nathan Reiff | May 17, 2025
View Top 4 ETFs for China Exposure After Tariff Relief
3 Alternative Asset Managers Are Raising Dividends by 5% to 25%
By Leo Miller | May 13, 2025
View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%
Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend
By Jeffrey Neal Johnson | May 9, 2025
View Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend
MarketBeat Week in Review – 05/05 - 05/09
By MarketBeat Staff | May 10, 2025
View MarketBeat Week in Review – 05/05 - 05/09

EQ, VTVT, RPTX, and VRCA Company Descriptions

Equillium NASDAQ:EQ

$0.36 -0.01 (-1.63%)

Closing price 03:51 PM Eastern

Extended Trading

$0.36 0.00 (0.00%)

As of 04:08 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Repare Therapeutics NASDAQ:RPTX

$1.49 +0.04 (+2.76%)

Closing price 03:59 PM Eastern

Extended Trading

$1.40 -0.09 (-5.70%)

As of 04:30 PM Eastern

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

Verrica Pharmaceuticals NASDAQ:VRCA

$0.58 -0.01 (-1.92%)

Closing price 04:00 PM Eastern

Extended Trading

$0.54 -0.05 (-8.14%)

As of 04:24 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

vTv Therapeutics NASDAQ:VTVT

$16.52 +0.53 (+3.28%)

Closing price 03:59 PM Eastern

Extended Trading

$16.76 +0.23 (+1.42%)

As of 04:05 PM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time